Downregulation of 18F-FDG uptake in PET as an early pharmacodynamic effect in 
treatment of non-small cell lung cancer with the mTOR inhibitor everolimus

Nogova, Lucia; Boellaard, Ronald; Kobe, Carsten; Hoetjes, Nikie; Zander, Thomas; Gross, Stefan Hubert; Dimitrijevic, Sasa; Pellas, Theodore; Eschner, Wolfgang; Schmidt, Katja; Bangard, Christopher; Hayes, Wendy; Thomas, Roman K.; Dietlein, Markus; Giaccone, Giuseppe; Hoekstra, Otto S.; Lammertsma, Adriaan A.; Wolf, Juergen

doi:10.2967/jnumed.109.065367

Local TagsRelease HistoryDetailsSummary

Downregulation of 18F-FDG uptake in PET as an early pharmacodynamic effect in treatment of non-small cell lung cancer with the mTOR inhibitor everolimus

Nogova, L., Boellaard, R., Kobe, C., Hoetjes, N., Zander, T., Gross, S. H., et al. (2009). Downregulation of 18F-FDG uptake in PET as an early pharmacodynamic effect in treatment of non-small cell lung cancer with the mTOR inhibitor everolimus. Journal of Nuclear Medicine, 50(11), 1815-1819. doi:10.2967/jnumed.109.065367.

Item is Released

show all hide all

Basic

show hide

Item Permalink: https://hdl.handle.net/11858/00-001M-0000-0026-D425-2 Version Permalink: https://hdl.handle.net/11858/00-001M-0000-0026-D426-F

Genre: Journal Article

Files

show Files

Locators

show

Creators

show

hide

Creators:
Nogova, Lucia¹, Author
Boellaard, Ronald¹, Author
Kobe, Carsten¹, Author
Hoetjes, Nikie¹, Author
Zander, Thomas², Author
Gross, Stefan Hubert¹, Author
Dimitrijevic, Sasa¹, Author
Pellas, Theodore¹, Author
Eschner, Wolfgang¹, Author
Schmidt, Katja¹, Author
Bangard, Christopher¹, Author
Hayes, Wendy¹, Author
Thomas, Roman K.³, Author
Dietlein, Markus⁴, Author
Giaccone, Giuseppe¹, Author
Hoekstra, Otto S.¹, Author
Lammertsma, Adriaan A.¹, Author
Wolf, Juergen¹, Author

Affiliations:
11. Department I of Internal Medicine, Center for Integrated Oncology, University Hospital Cologne, 50924 Cologne, Germany 2. Department of Nuclear Medicine and PET Research, VU University Medical Centre, Amsterdam, Netherlands 3. Department of Nuclear Medicine, Center for Integrated Oncology, University Hospital Cologne, Cologne, Germany 4. Novartis Pharma AG, Basel, Switzerland 5. Novartis Pharmaceuticals Corp., East Hanover, NJ, United States 6. Department of Radiology, Center for Integrated Oncology, University Hospital Cologne, Cologne, Germany 7. Novartis Institutes for BioMedical Research, Cambridge, MA, United States 8. Chemical Genomics Center of the Max Planck Society, Dortmund, Germany 9. Department of Medical Oncology, VU University Medical Center, Amsterdam, Netherlands, ou_persistent22
2Klinisches PET, Neurologische Abteilung, Max-Planck-Institut für neurologische Forschung, Managing Director: D. Yves von Cramon, Max Planck Institute for Metabolism Research, Managing Director: Jens Brüning, Max Planck Society, ou_2149663
3Funktionelle Krebsgenomforschung, Junior Research Groups, Max-Planck-Institut für neurologische Forschung, Managing Director: D. Yves von Cramon, Max Planck Institute for Metabolism Research, Managing Director: Jens Brüning, Max Planck Society, ou_2149656
4Translational Neurocircuitry, Research Groups, Max Planck Institute for Metabolism Research, Managing Director: Jens Brüning, Max Planck Society, ou_2149668

Content

show

hide

Free keywords: -

Details

show

hide

Language(s): eng - English

Dates: Date issued: 2009

Publication Status: Issued

Pages: -

Publishing info: -

Table of Contents: -

Rev. Type: Peer

Identifiers: eDoc: 441561
DOI: 10.2967/jnumed.109.065367

Degree: -

Event

show

Legal Case

show

Project information

show

Source 1

show

hide

Title: Journal of Nuclear Medicine

Source Genre: Journal

Creator(s):

Affiliations:

Publ. Info: -

Pages: - Volume / Issue: 50 (11) Sequence Number: - Start / End Page: 1815 - 1819 Identifier: ISSN: 01615505